Welcome to our dedicated page for Celularity news (Ticker: $CELU), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Celularity's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Celularity's position in the market.
Celularity (NASDAQ: CELU) has announced that data published in the Journal for ImmunoTherapy of Cancer highlights the benefits of its placental-derived T-Cell platform for CAR-T therapies. The study revealed that CAR-T cells from Celularity's platform demonstrated greater persistence, resistance to exhaustion, and efficacy compared to those derived from adult peripheral blood mononuclear cells (PBMCs). Key findings include longer telomeres and attenuated cytokine responses without loss of cytotoxicity. These advantages may lead to more effective and scalable CAR-T therapies. Dr. Robert Hariri, CEO of Celularity, emphasized the potential of their platform to deliver improved and durable allogeneic CAR-T products.